Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | | Iberia Pharm. India Share Price
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | | Iberia Pharm. India Share Price
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|
| Sales | 69.36 | 86.72 | 96.54 |
| Operating Expenses ⓘ + | 58.65 | 64.35 | 79.51 |
| Operating Profit ⓘ | 10.71 | 22.38 | 17.03 |
| Operating Profit Margin (%) | 15.4% | 25.8% | 17.6% |
| Other Income ⓘ + | 0.11 | 0.44 | 1.71 |
| Interest ⓘ | 0.11 | 1.84 | 1.72 |
| Depreciation ⓘ | 0.27 | 1.44 | 1.87 |
| Profit Before Tax ⓘ | 10.45 | 19.54 | 15.15 |
| Tax ⓘ | 2.63 | 5.35 | 4.02 |
| Profit After Tax | 7.82 | 14.19 | 11.13 |
| PAT Margin (%) | 11.3% | 16.4% | 11.5% |
| Adjusted EPS (₹) | 4.8 | 7.3 | 5.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 14.62 | 39.95 | 51.65 | ||||||||
| Debt + | 10.71 | 12.94 | 17.35 | ||||||||
| Minority Interest | 0 | 0 | 0 | ||||||||
| Trade Payables | 18.18 | 10.84 | 12.77 | ||||||||
| Others Liabilities ⓘ | 5.39 | 18.11 | 20.09 | ||||||||
| Total Liabilities ⓘ | 48.89 | 81.84 | 101.86 | ||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 6.79 | 14.22 | 13.45 | ||||||||
| CWIP ⓘ | 0.96 | 10.95 | 17.96 | ||||||||
| Investments ⓘ | 0 | 0 | 0 | ||||||||
| Inventories | 19.91 | 27.71 | 27.66 | ||||||||
| Trade Receivables | 16.08 | 21.65 | 21.18 | ||||||||
| Cash Equivalents | 0.72 | 1.09 | 7.60 | ||||||||
| Others Assets ⓘ | 4.42 | 6.23 | 14.02 | ||||||||
| Total Assets ⓘ | 48.89 | 81.84 | 101.86 | ||||||||
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -7.48 | -2.58 | 11.03 |
| Cash Flow From Investing Activity ⓘ + | -5.05 | -10.38 | -7.21 |
| Cash Flow From Financing Activity ⓘ + | 12.85 | 13.30 | 2.51 |
| Net Cash Flow ⓘ | 0.32 | 0.34 | 6.33 |
| PARTICULARS | Mar'24 | Mar'25 | Mar'26 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 53.49 | 52.01 | 24.31 | |||||||
| ROCE (%) | 41.54 | 53.47 | 26.89 | |||||||
| Asset Turnover Ratio | 1.42 | 1.33 | 1.05 | |||||||
| PAT to CFO Conversion(x) | -0.96 | -0.18 | 0.99 | |||||||
| Working Capital Days | ||||||||||
| Receivable Days | 84.60 | 79.40 | 81 | |||||||
| Inventory Days | 104.80 | 100.20 | 104.70 | |||||||
| Payable Days | 158.50 | 151.40 | 102.50 | |||||||

